Your Good Partner in Biology Research

重組抗體

產(chǎn)品名稱 貨號 規(guī)格
Phospho-GSK3B (Ser9) Recombinant Monoclonal Antibody CSB-RA009963A09phHU 100μl/50μl
Phospho-POLR2A (S2) Recombinant Monoclonal Antibody CSB-RA018327A02phHU 100μl/50μl
Phospho-POLR2A (S5) Recombinant Monoclonal Antibody CSB-RA018327A05phHU 100μl/50μl
Phospho-PRKAA2 (S491) Recombinant Monoclonal Antibody CSB-RA805325A491phHU 100μl/50μl
Phospho-MAPT (S324) Recombinant Monoclonal Antibody CSB-RA013481A324phHU 100μl/50μl
Phospho-MAPK3 (T202/Y204) + MAPK1 (T185/Y187) Recombinant Monoclonal Antibody CSB-RA013456A204phHU 100μl/50μl
Phospho-CREB1 (S133) Recombinant Monoclonal Antibody CSB-RA005947A133phHU 100μl/50μl
Phospho-ATM (S1981) Recombinant Monoclonal Antibody CSB-RA618770A1981phHU 100μl/50μl
Phospho-SNCA (S129) Recombinant Monoclonal Antibody CSB-RA021912A129phHU 100μl/50μl
Phospho-MAPK8/MAPK9/MAPK10 (T183/T183/T221) Recombinant Monoclonal Antibody CSB-RA013466A183phHU 100μl/50μl
Phospho-PTEN (S380) Recombinant Monoclonal Antibody CSB-RA018964A380phHU 100μl/50μl
Phospho-MLKL (S358) Recombinant Monoclonal Antibody CSB-RA850851A358phHU 100μl/50μl
Phospho-LAT (Y191) Recombinant Monoclonal Antibody CSB-RA012767A191phHU 100μl/50μl
Phospho-TP53 (S33) Recombinant Monoclonal Antibody CSB-RA024077A33phHU 100μl/50μl
Phospho-TP53 (S9) Recombinant Monoclonal Antibody CSB-RA024077A09phHU 100μl/50μl
Phospho-PRKDC (S2056) Recombinant Monoclonal Antibody CSB-RA018714A2056phHU 100μl/50μl
Phospho-RB1 (S780) Recombinant Monoclonal Antibody CSB-RA019386A780phHU 100μl/50μl
Phospho-MTOR (S2448) Recombinant Monoclonal Antibody CSB-RA008968A2448phHU 100μl/50μl
Phospho-PAK4/PAK5/PAK6 (S474/S560/S602) Recombinant Monoclonal Antibody CSB-RA017408A474phHU 100μl/50μl
Phospho-PTK2 (Y397) Recombinant Monoclonal Antibody CSB-RA018994A397phHU 100μl/50μl

關(guān)于重組抗體

與傳統(tǒng)抗體相比,重組抗體的優(yōu)勢具體如下:

  • 更高的一致性和重復(fù)性

    因為重組抗體是由一組獨特的基因發(fā)展而來的,所以抗體生產(chǎn)是可控且可靠的??梢员苊怆s交瘤細胞制備中的一些問題,如基因丟失、基因突變和細胞株漂移等。這使得抗體的批次間差異非常小,從而為您提供高度可重復(fù)的結(jié)果。

  • 更高的靈敏度和特異性

    利用重組技術(shù),更容易通過抗體工程提高抗體特異性和靈敏度。所需克隆的選擇過程發(fā)生在雜交瘤細胞和重組克隆階段,這使我們能夠選擇最優(yōu)的抗體質(zhì)量。

  • 易于擴展

    隨著抗體基因的分離,與傳統(tǒng)單克隆技術(shù)相比,抗體表達能夠以任何規(guī)模在更短的時間內(nèi)進行。這意味著我們可以在數(shù)周而非數(shù)月內(nèi)產(chǎn)生定制抗體。

  • 無動物高通量生產(chǎn)

    一旦分離出產(chǎn)生抗體的基因,就可以實現(xiàn)無動物體外生產(chǎn)。

重組抗體與傳統(tǒng)抗體的比較:

單克隆抗體 多克隆抗體 重組抗體
重復(fù)性 高;批次間差異小 更高;高純度,批次間差異更小
特異性 更強
生產(chǎn)周期 4到6個月的開發(fā);4到6周的生產(chǎn) 2到3個月的開發(fā)和生產(chǎn) 4個月的開發(fā);1到6周的生產(chǎn)
同型亞基轉(zhuǎn)換 困難 困難 方便
表達系統(tǒng) 小鼠腹水法和體外方法 通常在哺乳動物細胞(如兔) 通常在哺乳動物細胞系中,也可在特殊工程細胞系中表達,如酵母、細菌、昆蟲和轉(zhuǎn)基因植物
成本 生產(chǎn)成本較高;需要更專業(yè)的人員操作 成本相對較低 需要技術(shù)專長和較大的時間和金錢投入進行生產(chǎn)
人類免疫應(yīng)答 無法避免 無法避免 可避免

更多重組抗體概述點擊查看>>

引用文獻

S Antibody referenced in "A magneto-optical biochip for rapid assay based on the Cotton–Mouton effect of γ-Fe2O3@ Au core/shell nanoparticles", Journal of nanobiotechnology, 2021.

SARS-CoV-2 Spike RBD Nanobody referenced in "Potent antiviral activity of Agrimonia pilosa, Galla rhois, and their components against SARS-CoV-2", Bioorganic & Medicinal Chemistry, 2021.

HIF1A Antibody, CASP3 Antibody referenced in "PESV represses non-small cell lung cancer cell malignancy through circ_0016760 under hypoxia", Cancer cell international, 2021.

Phospho-ERN1 (S724) Antibody referenced in "The ER stress sensor inositol-requiring enzyme 1α in Kupffer cells promotes hepatic ischemia-reperfusion injury", Journal of Biological Chemistry, 2021.

CDK4 Antibody and CDK6 Antibody referenced in "Histone Deacetylase Inhibitor-Induced CDKN2B and CDKN2D Contribute to G2/M Cell Cycle Arrest Incurred by Oxidative Stress in Hepatocellular Carcinoma Cells Via Forkhead Box M1 Suppression", Journal of Cancer, 2021.

BIRC5 Antibody referenced in "LTBP4 Inhibits the Proliferation and Metastasis in Melanoma by Activating Hippo-YAP Signaling", Research Square, 2020.

查看更多 >>